Background {#Sec1}
==========

Breast cancer is the most common cancer in women worldwide \[[@CR1]\]. The disease is highly heterogeneous with wide variations in prognosis \[[@CR2]\]. Prognosis means the probability or risk that an outcome (such as deaths, complications, quality of life, pain, or disease regression) develops over a specific time, based on both clinical and non-clinical profiles \[[@CR3]\]. In breast cancer patients, 5-year relapse-free survival (RFS) ranges from 65 to 80% \[[@CR4]\], and 10-year overall survival (OS) ranges from 55 to 96% \[[@CR5]\].

Prognosis for breast cancer is important in several ways. Firstly, it informs patients about the future course of their illness \[[@CR3]\]. Two Australian surveys found that survival time information was desired by 87 and 85% of early and metastatic breast cancer patients, respectively \[[@CR6], [@CR7]\]. Secondly, prognosis is essential for breast cancer treatment: the more precise is the outcome predicted, the better a patient is allocated the right treatment \[[@CR3], [@CR8]--[@CR10]\]. For example, patients whose prognosis is very poor may be considered for aggressive treatments, while those with a good prognosis may be saved from overtreatment and its related side-effects and financial costs \[[@CR11], [@CR12]\]. Thirdly, prognosis can be used for the inclusion and stratification of patients in experimental studies \[[@CR8], [@CR9]\]. Finally, prognosis helps policy makers compare mortality rates among hospitals and institutions \[[@CR3], [@CR13]\].

Many models have been developed to predict breast cancer prognosis. The number of models has increased rapidly, accompanying with the great variance in terms of patients included, methods of development, predictors, outcomes, presentations, and performance in different settings \[[@CR11], [@CR14]\]. Nevertheless, to our knowledge, only two reviews of prognostic models for breast cancer have been conducted, but with limitations. An earlier review reported 54 models that were developed between 1982 and 2001, with a focus on model development methods rather than model performance in different populations \[[@CR11]\]. A more recent review included only 26 models published up to July 2012 \[[@CR14]\]. This systematic review was undertaken to identify all prognostic models that have been published up to 2017, and to assess how the models performed in different settings.

Methods {#Sec2}
=======

Study search {#Sec3}
------------

A systematic search was conducted in EMBASE, PUBMED, Web of Science, COCHRANE, and in specific breast cancer and oncology websites, including: American Society of Clinical Oncology (ASCO) <https://www.asco.org/>, Journal of the National Comprehensive Cancer Network (JNCCN) <http://www.jnccn.org/>, Memorial Sloan Kettering Cancer Centre (MSKCC) <https://www.mskcc.org/>, MD Anderson Cancer Centre <https://www.mdanderson.org/>, Mayo Clinic <http://www.mayoclinic.org/>, and European Society for Medical Oncology (ESMO) <http://www.esmo.org/>. A manual search in the bibliographies of selected articles was also conducted. The search terms used were "prognostic model", "breast cancer", and their synonyms (see details in Additional file [1](#MOESM1){ref-type="media"}).

Eligibility criteria {#Sec4}
--------------------

This review included all research articles that presented the development and/or validation of prognostic models for female breast cancer, were published in English prior to 1st January 2017 and were available in full text. The review was restricted to the models that were developed based on at least two different clinico-pathological factors and/or commonly used biomolecular factors, such as hormonal receptor status or human epidermal growth factor receptor 2 (HER2) status, and predicted mortality and/or recurrence of women who were diagnosed with primary breast cancer. Articles that reported the development of a model for specific patient groups (those with invasive ductal carcinoma or invasive lobular carcinoma, those who have undergone surgery) were included. Articles that presented the development of a model for rare histological subtypes of breast cancer or special types of patients (such as those with metastases, those with hormonal receptor negative or positive, those with node negative or positive, those with neoadjuvant or adjuvant therapy) were excluded due to their limited generalisability.

Study selection and data extraction {#Sec5}
-----------------------------------

Publications were screened in three levels - titles, abstracts, and full texts. From each selected article, relevant information was extracted into a data extraction sheet using the TRIPOD \[[@CR15]\] and CHAMRS checklist \[[@CR16]\], and included: authors, year of publication, objectives, name of models, study design, source of data, targeted populations, methods of development and/or validation, risk groups, outcomes, predictors, results of the development and/or validation, limitations and strengths.

The selected articles were categorised into three groups: those that presented model development, those that presented internal validation, and those that presented external validation. For the articles that presented the development of more than one model, we reviewed the best model only if the study indicated the best model, or we reviewed all the models presented if the study did not select the best model. Internal validation is defined here as the validation of a model in participants selected from the model development cohorts, or in patients recruited from the same source as in the development cohorts but at different times. External validation is defined as the validation of a model in patients from sources independent from the development cohorts \[[@CR8]\].

Assessment of risk of bias in individual studies {#Sec6}
------------------------------------------------

The risk of bias within individual studies was assessed by using a modified version of the QUIPS (QUality In Prognosis Studies) tool, which was originally designed to assess bias in studies of prognostic factors \[[@CR17], [@CR18]\]. The tool originally comprises six domains -- Study Participation, Prognostic Factor Measurement, Outcome Measurement, Statistical Analysis and Reporting, Study Confounding, and Study Attrition, each of which is guided by three to seven prompting items. The last two domains were omitted as these are not relevant to the studies included in this review. The overall rating for each of the remaining four domains was assigned as low, moderate, or high risk of bias \[[@CR17]\].

The risk of bias was assessed separately for development (and internal validation) studies and external validation studies. For articles that presented both model development and external validation, the risk of bias was assessed separately for each part. For articles that presented internal validation without model development, the risk of bias was assessed similarly to the external validation studies.

Results {#Sec7}
=======

The systematic search in the four databases generated 4084 records, supplemented by 11 publications found in other sources (Fig. [1](#Fig1){ref-type="fig"}**)**. We excluded 2466 duplicates. We screened the titles and then the abstracts of the remaining records and excluded 1355 records. We reviewed the full text of the remaining 274 articles and identified 96 eligible articles, of which 54 presented model development, 42 presented internal validation and 49 presented external validation. Twenty four studies that met the eligibility criteria but were not available in full text are presented in Additional file [2](#MOESM2){ref-type="media"} (model development) and Additional file [3](#MOESM3){ref-type="media"} (model validation).Fig. 1Flow diagram of the literature search process

Study characteristics {#Sec8}
---------------------

The studies were published between 1982 and 2016, mostly retrospective and hospital-based. Participants were mostly from Europe, Asia, and North America (Table [1](#Tab1){ref-type="table"}**)**.Table 1Characteristics of the studies selected for the systematic reviewCharacteristicsModel development studiesInternal validation studiesExternal validation studiesNumber of studies54 studies42 studies49 studiesNumber of models58 models42 models17 modelsYear of publication1982--20161982--20161987--2016Study design Prospective2 studies2 studies0 study Retrospective32 studies23 studies30 studies Unknown20 studies18 studies19 studiesSource of data Population-based14 studies11 studies12 studies Hospital-based31 studies29 studies33 studies RCT-based6 studies1 study4 studies Unknown3 studies2 studies0 studySample size75--433,27230--433,27248--387,262Number of events Deaths27--24,61027--24,61011--3902 Recurrences5--10305--9509--1188Country of participants Europe24 studies22 studies29 studies North America13 studies8 studies7 studies Asia11 studies10 studies11 studies Others2 studies (Australia)0 study3 studies (1 Australia. 1 New Zealand, 1 Brazil)Strengths concluded by the authors of the selected studies Adhere to good practice1 study1 study0 study Large sample size2 studies2 studies4 studies Patients diagnosed recently1 study1 study0 study Homogeneous source of data2 studies2 studies1 study Low proportion of missing data0 study0 study1 studyWeaknesses concluded by the authors of the selected studies Missing data11 studies11 studies8 studies Small sample size3 studies3 studies9 studies Patients treated with obsolete methods4 studies4 studies3 studies Heterogeneous source of data3 studies3 studies0 study Selection bias2 studies2 studies0 study Short-time follow-up1 study1 study0 study

Of the 54 model development studies identified, 42 developed only one model, nine developed more than one model and selected the best performing model(s) \[[@CR19]--[@CR27]\], whereas three studies developed more than one model but did not select the best model(s) \[[@CR28]--[@CR30]\]. In total, we reviewed 58 models. More detailed information about each development study is presented in Additional file [4](#MOESM4){ref-type="media"}.

Among the 42 internal validation studies, 38 developed models and validated them, while four only validated the existing models: three studies validated the Nottingham Prognostic Index (NPI) \[[@CR31]--[@CR33]\], and one validated the Morphometric Prognostic Index (MPI) \[[@CR34]\] (see details in Additional file [5](#MOESM5){ref-type="media"}).

Of the 49 external validation studies, 38 validated the existing models only, 10 developed new models and then validated them \[[@CR19], [@CR35]--[@CR43]\], and one externally validated an existing model (Adjuvant!) and then developed a new model \[[@CR44]\]. More detailed information about the external validation studies is presented in Additional file [6](#MOESM6){ref-type="media"}.

Risk of bias in individual studies {#Sec9}
----------------------------------

The risk of bias was assessed for 54 studies in the development part (Table [2](#Tab2){ref-type="table"}), and 53 studies in the validation part (Table [3](#Tab3){ref-type="table"}). In all the four domains of the QUIPS tool, most studies had low or moderate risk of bias while only a small number were at high risk of bias.Table 2Risk of bias within model development studiesNoCitationStudy ParticipationPrognostic Factor MeasurementOutcome MeasurementStatistical Analysis and Presentation1Asare et al. (2016) \[[@CR107]\]LowModerateModerateModerate2Baak et al. (1985) \[[@CR108]\]LowModerateLowModerate3Broet et al. (1999) \[[@CR109]\]LowModerateModerateLow4Brown et al. (1993) \[[@CR110]\]ModerateModerateLowModerate5Bryan et al. (1986) \[[@CR111]\]ModerateLowLowLow6Bucinski et al. (2005) \[[@CR112]\]HighModerateHighModerate7Campbell et al. (2010) \[[@CR19]\]LowLowModerateLow8Chao et al. (2014) \[[@CR20]\]ModerateHighLowModerate9Chen et al. (2016) \[[@CR41]\]ModerateHighLowLow10Cheng et al. (2006) \[[@CR30]\]LowModerateHighLow11Choi et al. (2009) \[[@CR25]\]LowHighLowModerate12Collan et al. (1994) \[[@CR113]\]ModerateLowLowModerate13de Laurentiis et al. (1999) \[[@CR43]\]LowModerateModerateModerate14Delen et al. (2005) \[[@CR27]\]ModerateModerateLowModerate15Eskelinen et al. (1992) \[[@CR10]\]ModerateLowModerateLow16Fan et al. (2011) \[[@CR56]\]LowModerateLowLow17Fleming et al. (1999) \[[@CR21]\]LowModerateLowModerate18Fuster et al. (1983) \[[@CR114]\]HighHighLowModerate19Gomez-Ruiz et al. (2004) \[[@CR97]\]ModerateHighHighModerate20Hawkins et al. (2002) \[[@CR89]\]ModerateLowModerateModerate21Haybittle et al. (1982) \[[@CR53]\]ModerateLowLowModerate22Jerez Aragones et al. (2004) \[[@CR115]\]ModerateHighLowModerate23Jerez et al. (2005) \[[@CR26]\]LowModerateHighLow24Jhajharia et al. (2016) \[[@CR116]\]ModerateHighLowModerate25M. Jung et al. (2013) \[[@CR44]\]LowModerateLowModerate26Kim et al. (2012) \[[@CR22]\]LowHighHighLow27Kim et al. (2016) \[[@CR117]\]ModerateHighHighLow28Lisboa et al. (2003) \[[@CR23]\]ModerateHighLowHigh29Y.Q. Liu et al. (2009) \[[@CR118]\]ModerateModerateLowModerate30Lovekin et al. (1991) \[[@CR119]\]HighModerateLowModerate31Masarwah et al. (2016) \[[@CR55]\]ModerateLowHighLow32Mazouni et al. (2011) \[[@CR120]\]ModerateModerateLowLow33Michaelson et al. (2011) \[[@CR42]\]ModerateHighLowModerate34Musial et al. (2005) \[[@CR121]\]ModerateModerateLowLow35Ni et al. (2014) \[[@CR122]\]ModerateModerateHighLow36Paik et al. (1990) \[[@CR123]\]ModerateLowLowModerate37Putter et al. (2006) \[[@CR124]\]ModerateModerateModerateModerate38Rakha et al. (2014) \[[@CR90]\]ModerateModerateLowModerate39Ravdin et al. (2001) \[[@CR125]\]LowHighModerateModerate40Ripley et al. (1998) \[[@CR29]\]ModerateHighHighModerate41Sanghani et al. (2007) \[[@CR126]\]HighHighHighModerate42Sanghani et al. (2010) \[[@CR38]\]LowHighModerateModerate43Shek & Godolphin (1988) \[[@CR127]\]LowModerateLowModerate44Suen & Chow (2006) \[[@CR91]\]LowLowModerateLow45Tokatli et al. (2011) \[[@CR28]\]ModerateModerateHighLow46Ture et al. (2009) \[[@CR24]\]ModerateHighHighLow47van Belle et al. (2010b) \[[@CR37]\]LowLowHighLow48van Nes et al. (2010) \[[@CR128]\]ModerateHighModerateModerate49Wen et al. (2015) \[[@CR129]\]LowModerateLowLow50Wen et al. (2016) \[[@CR57]\]LowModerateLowLow51Wishart et al. (2010b) \[[@CR40]\]LowHighLowLow52Wishart et al. (2012) \[[@CR35]\]ModerateModerateLowLow53Wishart et al. (2014) \[[@CR36]\]ModerateLowLowLow54Witteveen et al. (2015) \[[@CR39]\]LowModerateHighLowTable 3Risk of bias within model validation studiesNoCitationStudy ParticipationPrognostic Factor MeasurementOutcome MeasurementStatistical Analysis and Presentation1Aaltomaa et al. (1983) \[[@CR130]\]LowLowLowLow2Albergaria et al. (2011) \[[@CR75]\]ModerateModerateLowLow3Alexander et al. (1987) \[[@CR131]\]LowLowLowLow4Balslev et al. (1994) \[[@CR48]\]LowHighLowLow5Bhoo-Pathy et al. (2012) \[[@CR61]\]LowModerateModerateLow6Campbell et al. (2009) \[[@CR59]\]LowModerateLowLow7Campbell et al. (2010) \[[@CR19]\]ModerateLowModerateModerate8Carbone et al. (1999) \[[@CR132]\]ModerateLowLowLow9Chen et al. (2016) \[[@CR41]\]LowHighLowLow10Chollet et al. (2003) \[[@CR49]\]ModerateHighLowLow11Collan et al. (1998) \[[@CR98]\]ModerateLowLowLow12de Glas et al. (2014) \[[@CR66]\]LowModerateLowLow13de Glas et al. (2016) \[[@CR69]\]LowModerateLowLow14de Laurentiis et al. (1999) \[[@CR43]\]ModerateLowModerateModerate15D'Eredita et al. (2001) \[[@CR51]\]LowLowLowLow16Galea et al. (1992) \[[@CR32]\]ModerateModerateLowModerate17Green et al. (2016) \[[@CR133]\]LowModerateLowLow18Hajage et al. (2011) \[[@CR58]\]ModerateLowModerateLow19Hearne et al. (2015) \[[@CR47]\]LowLowLowLow20S.P. Jung et al. (2013) \[[@CR134]\]LowModerateLowLow21M. Jung et al. (2013) \[[@CR44]\]LowModerateModerateLow22Kindts et al. (2016) \[[@CR135]\]ModerateModerateModerateLow23Kollias et al. (1999) \[[@CR31]\]ModerateModerateLowModerate24Kuo et al. (2012) \[[@CR62]\]LowLowModerateLow25Laas et al. (2015) \[[@CR68]\]ModerateModerateModerateLow26Lende et al. (2010) \[[@CR136]\]LowModerateLowLow27M. Liu et al. (2010) \[[@CR74]\]LowModerateLowLow28Maishman et al. (2015) \[[@CR137]\]ModerateModerateLowLow29Megha et al. (2010) \[[@CR70]\]ModerateModerateLowLow30Miao et al. (2016) \[[@CR138]\]ModerateHighLowLow31Michaelson et al. (2011) \[[@CR42]\]LowHighLowModerate32Mojir Sheibani et al. (2013) \[[@CR65]\]LowLowModerateLow33Mook et al. (2009) \[[@CR64]\]LowModerateModerateLow34Okugawa et al. (2009) \[[@CR52]\]LowLowLowLow35Olivotto et al. (2005) \[[@CR45]\]LowHighLowLow36Plakhins et al. (2013) \[[@CR63]\]ModerateModerateLowLow37Quintyne et al. (2013) \[[@CR60]\]LowModerateModerateLow38Rejali et al. (2015) \[[@CR54]\]ModerateModerateModerateLow39Ribelles et al. (1997) \[[@CR139]\]ModerateLowLowLow40Sanghani et al. (2010) \[[@CR38]\]ModerateModerateModerateLow41Sidoni et al. (2004) \[[@CR71]\]ModerateLowLowLow42Sundquist et al. (1999) \[[@CR72]\]LowModerateLowLow43Todd et al. (1987) \[[@CR33]\]HighLowLowModerate44van Belle et al. (2010a) \[[@CR73]\]LowModerateLowLow45van Belle et al. (2010b) \[[@CR37]\]LowHighLowLow46van Diest & Baak (1991) \[[@CR34]\]LowModerateLowLow47Wishart et al. (2010b) \[[@CR40]\]LowHighLowLow48Wishart et al. (2011) \[[@CR46]\]LowHighLowLow49Wishart et al. (2012) \[[@CR35]\]LowHighLowLow50Wishart et al. (2014) \[[@CR36]\]LowModerateLowLow51Witteveen et al. (2015) \[[@CR39]\]LowModerateHighLow52Wong et al. (2015) \[[@CR67]\]LowModerateLowLow53Yadav et al. (2015) \[[@CR50]\]ModerateModerateLowHigh

Model development {#Sec10}
-----------------

Of the 58 models identified, 49 were developed independently, while nine were derived from the existing models, of which five were derived from the NPI, one from Adjuvant!, one from IBTR! (the model predicts the risk of ipsilateral breast tumour recurrence), and two from PREDICT v1.1. The version PREDICT v1.2, also called PREDICT+, added HER2 status as a predictor into the first version PREDICT v1.1 \[[@CR35]\]. The version PREDICT v1.3 added Ki67, a nuclear protein used as a marker of cell proliferation, into PREDICT v1.2 \[[@CR36]\].

The models predicted mortality (*n* = 28), recurrence (*n* = 23), or both (*n* = 7), mostly based on participants in Europe (*n* = 25), followed by Asia (*n* = 13), North America (*n* = 12), and Australia (*n* = 1). Cox proportional hazards (PH) regression (*n* = 32) was the most commonly used method for model development, followed by artificial neural networks (*n* = 6), decision trees (*n* = 4), logistic regression (*n* = 3), and Bayesian methods (*n* = 3). The most commonly used predictors include nodal status (*n* = 49), tumour size (*n* = 42), tumour grade (*n* = 29), age at diagnosis (*n* = 24), and oestrogen receptor (ER) status (*n* = 21). The models were presented as regression formula (*n* = 13), followed by online tools (*n* = 8), decision trees (*n* = 5), nomograms (*n* = 4) and score chart (*n* = 1) (Table [4](#Tab4){ref-type="table"}).Table 4Characteristics of the modelsNumber of models^a^Total58 modelsTypes of models New models49 models Modified models9 modelsYear of development1982--2016 1982--19895 models 1990--199911 models 2000--200917 models 2010--201625 modelsCountry of participants for model development Europe25 models Asia13 models North America12 models Others1 model (Australia) Unknown or from several trials7 modelsMethod of model development Cox PH regression32 models Artificial neural networks6 models Decision tree4 models Logistic regression3 models Bayesian method3 models Multistate model2 models Support vector machine2 models Others6 modelsOutcomes Mortality28 models Recurrence23 models Both7 modelsPredictors Age at diagnosis24 models Nodal status49 models Tumour size42 models Tumour grade29 models Lympho-vascular invasion (LVI)8 models Stage8 models ER status21 models Progesterone receptor (PR) status10 models HER2 status13 models Treatment17 models OthersMitotic activity index (MAI), histological subtypes, comorbidity, menopausal status, etc.Presentation of model Regression formula13 models Online tool8 models Decision tree5 models Nomogram4 models Score chart1 model No report27 modelsNumber of risk groups 53 models 43 models 39 models 26 models No report/No risk group33 modelsValidation No validation11 models Internal validation43 models External validation17 models^a^Total number of models is 58. Where each model can fit more than one category, the number of models may not always total 58

Seventeen models have been externally validated by independent researchers (*n* = 8) or by the model developers (*n* = 15). These models were developed to support clinical decision making (*n* = 14) or evaluating the prognostic value of specified clinical factors (*n* = 3) (Additional file [7](#MOESM7){ref-type="media"}). Additional file [8](#MOESM8){ref-type="media"} presents the characteristics of these models.

The models that were most frequently validated include Adjuvant! (*n* = 17), the NPI (*n* = 15), and PREDICT v1.3 (*n* = 5). Among the 17 studies that externally validated Adjuvant!, three had high risk of bias in Prognostic Factor Measurements \[[@CR35], [@CR45], [@CR46]\], one was at low risk of bias across the QUIPS domains \[[@CR47]\], while the remaining studies had low or moderate risk of bias. Among the 15 studies that externally validated the NPI, three were at high risk of bias in Prognostic Factor Measurement \[[@CR37], [@CR48], [@CR49]\], one was at high risk of bias in Statistical Analysis and Presentation \[[@CR50]\], three were at low risk across the domains \[[@CR47], [@CR51], [@CR52]\], and the rest had low or moderate risk of bias. All the five studies that externally validated PREDICT v1.3 had low or moderate risk of bias (Table [5](#Tab5){ref-type="table"}).Table 5Risk of bias within the external validation studies by modelsNoModelValidated byAuthors(Year of publication)Risk of bias domainStudy ParticipationPrognostic Factor MeasurementOutcome MeasurementStatistical Analysis and Presentation1Adjuvant!Model developer(s)Mook et al. (2009) \[[@CR64]\]LowModerateModerateLowOlivotto et al. (2005) \[[@CR45]\]LowHighLowLowWishart et al. (2011) \[[@CR46]\]LowHighLowLowWishart et al. (2012) \[[@CR35]\]LowHighLowLowIndependent researcher(s)Campbell et al. (2009) \[[@CR59]\]LowModerateLowLowHajage et al. (2011) \[[@CR58]\]ModerateLowModerateLowHearne et al. (2015) \[[@CR47]\]LowLowLowLowM. Jung et al. (2013) \[[@CR44]\]LowModerateModerateLowLaas et al. (2015) \[[@CR68]\]ModerateModerateModerateLowLende et al. (2010) \[[@CR136]\]LowModerateLowLowPlakhins et al. (2013) \[[@CR63]\]ModerateModerateLowLowQuintyne et al. (2013) \[[@CR60]\]LowModerateModerateLowRejali et al. (2015) \[[@CR54]\]ModerateModerateModerateLowde Glas et al. (2014) \[[@CR66]\]LowModerateLowLowBhoo-Pathy et al. (2012) \[[@CR61]\]LowModerateModerateLowKuo et al. (2012) \[[@CR62]\]LowLowModerateLowMojir Sheibani et al. (2013) \[[@CR65]\]LowLowModerateLow2NPIModel developer(s)van Belle et al. (2010a) \[[@CR73]\]LowModerateLowLowIndependent researcher(s)Albergaria et al. (2011) \[[@CR75]\]ModerateModerateLowLowBalslev et al. (1994) \[[@CR48]\]LowHighLowLowChollet et al. (2003) \[[@CR49]\]ModerateHighLowLowD'Eredita et al. (2001) \[[@CR51]\]LowLowLowLowHearne et al. (2015) \[[@CR47]\]LowLowLowLowM. Liu et al. (2010) \[[@CR74]\]LowModerateLowLowMegha et al. (2010) \[[@CR70]\]ModerateModerateLowLowOkugawa et al. (2009) \[[@CR52]\]LowLowLowLowQuintyne et al. (2013) \[[@CR60]\]LowModerateModerateLowRejali et al. (2015) \[[@CR54]\]ModerateModerateModerateLowSidoni et al. (2004) \[[@CR71]\]ModerateLowLowLowSundquist et al. (1999) \[[@CR72]\]LowModerateLowLowvan Belle et al. (2010b) \[[@CR37]\]LowHighLowLowYadav et al. (2015) \[[@CR50]\]ModerateModerateLowHigh3PREDICT v1.3Model developer(s)Wishart et al. (2014) \[[@CR36]\]LowModerateLowLowIndependent researcher(s)de Glas et al. (2016) \[[@CR69]\]LowModerateLowLowLaas et al. (2015) \[[@CR68]\]ModerateModerateModerateLowPlakhins et al. (2013) \[[@CR63]\]ModerateModerateLowLowWong et al. (2015) \[[@CR67]\]LowModerateLowLow4Cancer MathModel developer(s)Michaelson et al. (2011) \[[@CR42]\]LowHighLowModerateIndependent researcher(s)Laas et al. (2015) \[[@CR68]\]ModerateModerateModerateLowMiao et al. (2016) \[[@CR138]\]ModerateHighLowLow5MPIIndependent researcher(s)Aaltomaa et al. (1983) \[[@CR130]\]LowLowLowLowCarbone et al. (1999) \[[@CR132]\]ModerateLowLowLowCollan et al. (1998) \[[@CR98]\]ModerateLowLowLow6IBTR!2.0Model developer(s)Sanghani et al. (2010) \[[@CR38]\]ModerateModerateModerateLowIndependent researcher(s)S.P. Jung et al. (2013) \[[@CR134]\]LowModerateLowLowKindts et al. (2016) \[[@CR135]\]ModerateModerateModerateLow7Paik et al. (1990)Independent researcher(s)Ribelles et al. (1997) \[[@CR139]\]ModerateLowLowLow8Lovekin et al. (1991)Independent researcher(s)Ribelles et al. (1997) \[[@CR139]\]ModerateLowLowLow9PREDICT v1.1Model developer(s)Wishart et al. (2010b) \[[@CR40]\]LowHighLowLowWishart et al. (2011) \[[@CR46]\]LowHighLowLowWishart et al. (2012) \[[@CR35]\]LowHighLowLow10PREDICT v1.2Model developer(s)Maishman et al. (2015) \[[@CR137]\]ModerateModerateLowLowWishart et al. (2014) \[[@CR36]\]LowModerateLowLowWishart et al. (2012) \[[@CR35]\]LowHighLowLow11iNPIModel developer(s)van Belle et al. (2010a) \[[@CR73]\]LowModerateLowLow12NPI+Model developer(s)Green et al. (2016) \[[@CR133]\]LowModerateLowLow13INFLUENCEModel developer(s)Witteveen et al. (2015) \[[@CR39]\]LowModerateHighLow14OPTIONSModel developer(s)Campbell et al. (2010) \[[@CR19]\]ModerateLowModerateModerate15Chen et al. (2016)Model developer(s)Chen et al. (2016) \[[@CR41]\]LowHighLowLow16de Laurentiis et al. (1999)Model developer(s)de Laurentiis et al. (1999) \[[@CR43]\]ModerateLowModerateModerate17Bryan et al. (1986)Model developer(s)Alexander et al. (1987) \[[@CR131]\]LowLowLowLowTotal number of validation studies is 49. Since some studies validated more than one model, the number of studies does not total 49 

While the web-based programmes Adjuvant! and PREDICT v1.3 estimate the possible survival time for breast cancer patients, the NPI assigns a prognostic index (PI) score to each individual patient based on the calculation *(0.2x tumour size in cm) + lymph node stage + tumour grade*. Originally, the NPI was developed based on the lymph node stage, but later the authors suggested that the number of involved nodes can replace the lymph node stage \[[@CR32]\]. At the outset, a patient will be classified into one of three prognostic groups based on their NPI score: good prognostic group (PI\< 3.4), moderate prognostic group (3.4 ≤ PI≤5.4), and poor prognostic group (PI\> 5.4) \[[@CR53]\]. Some validation studies of the NPI further divided the samples into six smaller prognostic groups \[[@CR47], [@CR54]\].

Model validation {#Sec11}
----------------

### Internal validation {#Sec12}

Forty two models were internally validated by comparing the predicted outcomes to (a) the observed outcomes (*n* = 20); (b) the outcomes predicted by the NPI or Adjuvant! (*n* = 7); (c) the outcomes predicted by prognostic factors (*n* = 4); or (d) the outcomes predicted by other newly developed models (*n* = 15). The sampling methods for internal validation were cross-validation (*n* = 13), random-splitting (*n* = 11), or bootstrap (*n* = 5); some internal validation cohorts were exactly the same to the development cohorts (*n* = 13), or they were the development cohorts with longer follow-up (*n* = 1), or they were specific subgroups of the development cohorts (*n* = 1), or they were the combination of the development cohorts and the newly recruited patients in the same centres (*n* = 1), or they were different patients from the development cohorts but in the same hospitals (*n* = 1). The models were assessed for overall performance (*n* = 3), calibration (the level of agreement between the predicted and observed outcomes) (*n* = 12), discrimination (the extent to which a model can discriminate patients with the outcomes and those without the outcomes) (*n* = 28), and clinical usefulness (*n* = 13). Brier scores (*n* = 2), calibration plots (*n* = 7), Kaplan-Meier curves (*n* = 23), and accuracy rates (*n* = 11) were most commonly used to assess the models' overall performance, calibration, discrimination, and clinical usefulness, respectively (Table [6](#Tab6){ref-type="table"}**)**.Table 6Validation methodsDomainMeasureDescriptionInternal validationExternal validationOverall performanceMeasuring the distance between the predicted and actual outcomes \[[@CR9]\]3 studies2 studiesR^2^The amount of variability in outcomes that is explained by the model \[[@CR9]\]1 study1 studyBrier scoreA measure of the average discrepancy between the true disease status and the predicted probability of developing the disease \[[@CR85]\]2 studies1 studyCalibrationThe level of agreement between the observed and predicted outcomes \[[@CR9]\]12 studies32 studiesCalibration plotHaving predictions on the *x* axis, and the observed outcome on the *y* axis \[[@CR9]\]7 studies20 studiesSMR (Standardised mortality ratio)The difference from the predicted calibration line and the ideal line in calibration plot \[[@CR69]\]0 study1 studyE/ORatio between the predicted and observed outcomes \[[@CR100]\]3 studies2 studiesE-OAbsolute difference between the predicted and observed outcomes2 studies28 studiesHosmer-Lemeshow goodness-of-fit testThe ability of a model to fit a given set of data \[[@CR9]\]4 studies5 studiesDiscriminationThe extent to which the model can discriminate patients with the outcome and those without the outcome \[[@CR9]\]28 studies37 studiesKaplan-Meier curveThe probability of surviving in a given length of time while considering time in many small intervals \[[@CR140]\]23 studies20 studiesLog-rank testTesting the null hypothesis that there is no difference between populations in the probability of an event at any time point \[[@CR141]\]16 studies18 studiesC-indexThe probability that, for a randomly chosen pair of patients, the one who actually experienced the event of interest has a higher predicted value than the one who has not experienced the event \[[@CR85]\]11 studies12 studiesAUCArea under the receiving operating characteristic curve is identical to C-index for a model with binary outcome \[[@CR9]\]11 studies12 studiesCPEConcordance probability estimate represents the pairwise probability of lower patient risk given longer survival time \[[@CR142]\]0 study1 studyClinical usefulnessThe ability to make better decisions with a model than without it \[[@CR9]\]13 studies1 studyAccuracy rate$\documentclass[12pt]{minimal}
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Overall, most models performed well in the internal validation cohorts, some even showed better performance than the existing models \[[@CR19], [@CR22], [@CR37], [@CR44], [@CR55], [@CR56]\] or prognostic factors \[[@CR43], [@CR53], [@CR57]\].

### External validation {#Sec13}

Only 17 models have been externally validated by comparing the predicted outcomes with the observed outcomes (*n* = 35), with the outcomes predicted by other models (*n* = 10), or with the outcomes predicted by single prognostic factors (*n* = 4). Participants were recruited in countries different from the development cohorts (*n* = 39) or in the same countries but different centres/sources (*n* = 9). The models were assessed for overall performance (*n* = 2) (using explained variation R^2^ (*n* = 1) and Brier score (*n* = 1)); calibration (*n* = 32) (mainly using calibration plots (*n* = 20) and/or the comparison of the predicted (E) to the observed outcomes (O) (*n* = 30)); discrimination (*n* = 37) (mainly using Harrell's C-index/AUC (Area under the Receiver operating characteristic (ROC) curve) (*n* = 22), Kaplan-Meier curve (*n* = 20), and/or log-rank test (*n* = 18)); and clinical usefulness (*n* = 2) (using accuracy rate (*n* = 2) and sensitivity/specificity (*n* = 1)). Some studies that compared two or more models tested the agreement between the models (*n* = 4), using Kappa coefficient (κ) (*n* = 1) and correlation coefficients (Pearson or Spearman) (*n* = 3). Univariate (*n* = 10) and multivariate analysis (*n* = 6) were used to test if prognostic factors and prognostic scores were significant to outcomes (Table [6](#Tab6){ref-type="table"}). A summary of the external validation studies is presented in Additional file [9](#MOESM9){ref-type="media"}.

In general, the models performed less accurately in some independent populations, particularly in patients with high risk, in young and elderly patients. For example, Adjuvant! predicted prognosis accurately in patients from France \[[@CR58]\], Canada \[[@CR45], [@CR46]\], and those with low grade tumours, but less accurate in patients from UK \[[@CR59]\], Ireland \[[@CR60]\], Malaysia \[[@CR61]\], South Korea \[[@CR44]\], Taiwan \[[@CR62]\], those with lympho-vascular invasion \[[@CR45], [@CR61]\], BRCA1-mutation carriers \[[@CR63]\], and those with high grade tumours \[[@CR44], [@CR58], [@CR59], [@CR61], [@CR62]\]. Studies showed inconsistent results of Adjuvant! in patients aged 40 years or less \[[@CR35], [@CR44]--[@CR47], [@CR54], [@CR58], [@CR59], [@CR61], [@CR62], [@CR64]\] and elderly patients \[[@CR45], [@CR46], [@CR54], [@CR59], [@CR61], [@CR65], [@CR66]\]. Similarly, PREDICT v1.3 performed well in Malaysian patients \[[@CR67]\], but less accurately in patients with BRCA1 mutations \[[@CR63]\], patients aged 40 years or less \[[@CR67]\], and those with ER positive and HER2 negative tumours \[[@CR68]\], and inconsistently in elderly patients \[[@CR67], [@CR69]\]. An exception is the NPI, which performed well in most populations, including patients from Italy \[[@CR51], [@CR70], [@CR71]\], Sweden \[[@CR72]\], Denmark \[[@CR48]\], Belgium \[[@CR73]\], Norway \[[@CR37]\], Japan \[[@CR52]\], India \[[@CR50]\], New Zealand \[[@CR37]\], patients aged 40 years or less \[[@CR47]\], metastatic patients \[[@CR74]\], those with triple negative breast cancer \[[@CR75]\], and those treated with neoadjuvant chemotherapy \[[@CR49]\].

### Studies that compared different models in independent datasets {#Sec14}

In the three studies that compared the NPI and Adjuvant! conducted by independent researchers, no model was shown to be better than the other. One study showed that both models performed accurately in the overall cohort of Iranian patients, but less accurately in some subgroups \[[@CR54]\]. Another study found that Adjuvant! showed better discrimination ability than the NPI in Irish breast cancer patients, although Adjuvant! underestimated the 10-year OS \[[@CR60]\]. However, the third study showed that, in British breast cancer patients aged 40 years or less, the NPI's prediction was nearly similar to the observed outcomes, while Adjuvant! seemed to overestimate the 10-year OS, although the study power was not sufficient to generate a statistically significant difference \[[@CR47]\] (see details in Additional file [10](#MOESM10){ref-type="media"}).

None of the three models compared by independent researchers-- PREDICT v1.3, Adjuvant!, and CancerMath-- was found to be superior. In the studies that compared PREDICT v1.3 and Adjuvant!, both did not predict the 10-year OS well in BRCA1-mutation carriers \[[@CR63]\] and in patients aged 65 years or more \[[@CR66], [@CR69]\], with statistically significant differences between the predicted and observed outcomes (*P* \< 0.05). PREDICT v1.3 accurately predicted the 5-year OS in elderly patients, though not in all subgroups, but the authors could not compare that model with Adjuvant! because the latter did not predict the 5-year OS \[[@CR69]\]. When PREDICT v1.3, Adjuvant!, and CancerMath were compared in patients with ER positive and HER2 negative tumours, all the three models inaccurately predicted the 10-year OS, with statistically significant differences between the predicted and observed outcomes (*P* \< 0.05) \[[@CR68]\] (see details in Additional file [10](#MOESM10){ref-type="media"}**)**.

There are four studies that developed new models, and then compared them to existing models in independent datasets (see details in Additional file [11](#MOESM11){ref-type="media"}). In its development study, PREDICT v1.1 showed better performance than Adjuvant! in predicting 10-year breast cancer specific survival (BCSS), but poorer performance in 10-year OS in the overall cohort \[[@CR46]\]. PREDICT v1.1 was better in some sub-groups (10-year OS in patients with grade 3 tumours, lymphovascular positive tumours, and node negative tumours; 10-year BCSS in patients with node positive tumours, tumour size \> 21 mm, and ER positive tumours), whereas Adjuvant! was better in others (10-year OS in patients with tumour size \> 21 mm, grade 2 tumours, and ER positive tumours; 10-year BCSS in patients with grade 3 tumours, ER negative tumours, and node negative tumours) \[[@CR46]\]. In its development study, PREDICT v1.2 showed significantly better performance than PREDICT v1.1 and Adjuvant! in the HER2 positive subgroup, possibly because it was developed by adding HER2 status as a prognostic factor into PREDICT v1.1 \[[@CR35]\]. However, in the overall cohort, Adjuvant! was better in predicting OS while both versions of PREDICT were better in predicting BCSS \[[@CR35]\]. The development study of the iNPI showed that this version discriminated slightly better than the original version NPI, but the difference was not significant \[[@CR37]\]. The development study of PREDICT v1.3 showed that this new version improved both calibration and discrimination compared to the previous version PREDICT v1.2 in patients with ER positive tumours \[[@CR36]\].

Discussion {#Sec15}
==========

This study reviewed 96 articles that presented the development and/or validation of prognostic models for breast cancer. To our knowledge, this is the most comprehensive review of prognostic models for breast cancer. A previous review reported only six models based on clinico-pathological factors \[[@CR14]\]. However, our findings may be affected by publication bias \[[@CR8], [@CR76]\] as well as the diversity of terms used in prognostic research \[[@CR14], [@CR77]\]. The review may have missed some relevant studies that were published after December 2016, for example, PREDICT v2.0, which added age at diagnosis as a predictor into PREDICT v1.3 \[[@CR78]\].

Due to the heterogeneity of study designs, inclusion criteria, measurement techniques, methods of analysis, and methods of handling of continuous variables, meta-analysis was not undertaken as recommended previously \[[@CR76], [@CR79]\]. Instead, we assessed the risk of bias for each individual study using the modified QUIPS tool.

The original QUIPS tool was developed to assess bias in studies establishing the relationship between a prognostic factor and an outcome \[[@CR17]\], in which confounders may play an important role. In contrast, we are interested in outcome prediction studies where causality and confounding are not a concern \[[@CR9]\]. Therefore, we did not assess the confounding issue of the selected articles. We also omitted the domain of Study Attrition because, although most of the selected studies described attempts to track loss to follow-up to some extent, none of them reported specific information required by the QUIPS tool (including: the proportion of study sample dropping out of the study, attempts to collect their information, reasons for loss to follow-up, their key characteristics, and if these characteristics are different from those who completed the study \[[@CR17]\]).

We found that most studies were at moderate or low risk of bias, which contrasts with the findings in other systematic reviews that most studies were at poor quality \[[@CR11], [@CR77]\]. However, the previous reviews did not report the detailed quality assessment of each study.

Most studies included in this review used a retrospective design, and therefore had issues related to missing data and a lack of consistency in predictor and outcome measurement \[[@CR9], [@CR11], [@CR77]\]. Prospective cohort studies have been suggested as the best design for predictive modelling because they enable not only clear and consistent definitions but also prospective measurement of predictors and outcomes \[[@CR3], [@CR9]\].

Similar to the previous systematic reviews \[[@CR8], [@CR77], [@CR80], [@CR81]\], we found that most studies (59%) did not report, or did not satisfy the suggested minimum requirements for the numbers of events, i.e., 10 events per candidate variable for model development studies, and 100 events for model validation studies \[[@CR11], [@CR82]--[@CR87]\]. A small number of events could mislead the results of validation measures, for example, misleadingly high value of the C-index \[[@CR85]\].

We found that the most commonly used prognostic factors in the models were nodal status, tumour size, and tumour grade, followed by age at diagnosis and ER status, as reported in other reviews \[[@CR11], [@CR88]\]. The NPI was one of the simplest and oldest models, and included only nodal status, tumour size, and tumour grade. There are several attempts to improve the prognostic values of the NPI by adding other novel predictors, such as age at diagnosis \[[@CR89]\], hormonal receptor status \[[@CR37], [@CR89], [@CR90]\], and HER2 status \[[@CR37], [@CR55], [@CR90], [@CR91]\]. However, such modification has not been proven to be better than the NPI in independent populations. Future research may evaluate the added prognostic value of other important variables to the NPI and other models.

The use of gene expression or novel biomolecular factors is increasing due to their potential to provide molecular phenotyping that recognises distinct tumour categorisations not evident by traditional factors \[[@CR92], [@CR93]\]. However, we excluded models based on genetic profiles or novel biomolecular factors because these factors are not yet widely adopted in clinical practice. Additionally, since models that include both genetic and traditional factors are suggested to be superior to those based on either set of features alone \[[@CR94], [@CR95]\], studies of the prognostic value of any new marker should look at the extra benefit of including it when traditional clinico-pathological variables are also included.

The most commonly used method for model development was Cox PH regressions as reported in other reviews \[[@CR11], [@CR96]\]. Cox PH regressions are simple but have been criticised because the PH assumption may not always hold, since the strengths of prognostic factors change over time in the "real world" \[[@CR19], [@CR29], [@CR97]\]. To address this, alternative methods such as artificial neural networks, support vector machines, or multistate models have been applied. These models may perform better than Cox PH models but have not been validated in independent populations, limiting generalisability \[[@CR22]--[@CR24], [@CR26]\]. Furthermore, clinical validity is more important than statistical validity \[[@CR11]\]. As the models developed based on Cox PH regressions, such as the NPI or PREDICT, showed good performance in many populations, Cox PH regressions will still dominate the literature on model development methods.

Differences in the methodological issues pointed out in our review may be explained by differences in the purpose of developing the model (e.g., to support clinical decision making, to evaluate the prognostic value of a specific factor, or to compare statistical methods used to develop the model). However, not many developers explicitly stated the purposes of their models. Nevertheless, the models that have gone to further external validation were developed mainly to support clinical decision making. These models were considered useful in clinical practice.

Only one of 49 external validation studies in our review tested "clinical usefulness", which was defined by the authors as the ability for a model to classify patients into low risk and high risk groups better than without that model, and the measure used was accuracy rate \[[@CR98]\]. However, a model's ability to classify patients into two risk groups may not reflect its usefulness in clinical settings. A prognostic model can be useful if it classifies patients into more than two risk groups to influence therapy or to save patients from unnecessary treatments or to estimate survival time for patients \[[@CR8]\]. Future research may consider more relevant measures to assess clinical usefulness such as the improvement of clinical decision making when applying a model, patients' insights about model reports, or how doctors communicate with patients about model results.

Previous reviews reported that Hosmer-Lemeshow goodness-of-fit test was used most frequently to test the deviations in calibration plots \[[@CR77], [@CR81]\] but we found that the difference between the predicted and observed outcomes was more commonly used (Table [6](#Tab6){ref-type="table"}). Steyerberg and Vergouwe (2014) did not recommend the Hosmer-Lemeshow goodness-of-fit test because it only provides a *p*-value instead of providing the direction and magnitude of miscalibration \[[@CR99]\]. This test has also been criticised for being arbitrary and imprecise as the p-value is dependent on miscalibration and sample size \[[@CR99]\]. Instead, Steyerberg and Vergouwe (2014) advocated the use of the intercept of the calibration plot, also called calibration-in-the-large \[[@CR99]\], which is closely related to the difference between the predicted and observed outcomes, either absolute or relative difference \[[@CR100]\].

We found that C-index/AUC was the most commonly used method to assess discrimination, followed by Kaplan-Meier curves and log-rank tests, as reported in previous systematic reviews in several clinical fields \[[@CR9], [@CR77], [@CR96]\]. Log-rank tests were not recommended because they do not give an estimate of the magnitude of the separation of the risk groups \[[@CR96]\]. In contrast, C-index, or AUC for a binary endpoint, was advocated by several authors \[[@CR99]\].

This review focused on models that have been externally validated in several settings by independent researchers for many reasons. Firstly, external validation is preferable to internal validation to test a model's transportability as the case-mix (or the distribution of predictors) in an independent population is unlikely to be identical with that in the model development population \[[@CR85]\]. Secondly, to enhance the generalisability of a model, it should ideally be validated in different settings with diversity of case-mixes \[[@CR85]\]. A model with good performance in diverse settings is more likely to be generalisable to a plausibly related, but untested population \[[@CR13], [@CR85], [@CR86]\]. Finally, a reliable model should be tested by independent researchers in different settings \[[@CR8], [@CR101]\]. If model development and external validation are undertaken by the same researchers, there may be a temptation to revise the model to fit the external validation data \[[@CR8]\]. A clear distinction between the external validation studies conducted by independent researchers and by model developers should be made to reduce inflated findings and "spin" \[[@CR102]--[@CR104]\].

The studies that compared Adjuvant!, CancerMath, PREDICT v1.3, and the NPI in independent datasets by independent researchers did not find the superiority of one model over the others. When they were validated individually, only the NPI performed well in most independent populations, whereas the other models were accurate in just some populations. The NPI has been advocated by several authors and is one of the few models that are used in clinical practice \[[@CR11]\]. The advantage of the NPI is its simplicity, which is an important criterion in developing a useful model \[[@CR105]\]. Additionally, the model shows good reducibility and transportability because it performed well in diverse settings when validated by independent researchers. The model has good discrimination in most populations, and is therefore clinically useful because it classifies patients into risk groups to influence therapy or save patients from unnecessary treatments \[[@CR8], [@CR11]\]. However, most studies that validated the NPI only assessed its discrimination but not calibration, because the model cannot estimate prognosis of individual patients. Some studies assigned OS for all patients in the same NPI group based on previous reports \[[@CR47], [@CR54], [@CR73]\]. This practice is criticised as inappropriate, since estimates based on data at a period in the past are probably not well calibrated for patients today. Advanced treatments, such as hormonal therapies or targeted therapies, in addition to improvement in detection and diagnosis, may improve the survival within the NPI groups \[[@CR106]\]. Regular updates would be required for better prediction of prognosis for each group.

The performance of a particular model may vary across different populations. For example, the NPI, a UK-based model, performed well in most countries in Europe (Italy, Sweden, Denmark, Belgium, Norway), and even in Asia (Japan, India), but was less accurate in Irish patients. The US-based model Adjuvant! showed good performance in a large Dutch population, but poor performance in patients from the UK or Asia (Malaysia, South Korea, Taiwan). Therefore, a reliable validation study should be conducted before a model is applied in other populations.

Most studies in our review showed that models were less accurate in patients aged under 40 years or over 65 years, although some studies showed opposite results. Likewise, a previous review concluded that Adjuvant! was less accurate in young and elderly patients in most studies \[[@CR14]\]. However, most validation studies lack generalisability because they were based on small numbers of events or did not report the numbers of events. Only a few studies with appropriate numbers of events were designed to assess models' performance in young and elderly patients only. These studies found that PREDICT v1.3 was less accurate in predicting 10-year OS \[[@CR69]\], whereas Adjuvant! overpredicted 10-year OS and event-free survival (EFS) in Dutch elderly patients \[[@CR66]\]. Nonetheless, it is difficult to know if the poor performance of models in young and elderly patients was attributable to age only, or to other effect modifiers such as ethnicity.

Conclusion {#Sec16}
==========

We reviewed the development and/or validation of 58 models predicting mortality and/or recurrence for female breast cancer. These models varied in terms of methods of development and/or validation, predictors, outcomes, and patients included. Most models have been developed in Europe, Asia, and North America. We found that models performed well in internal validation cohorts, but the results were unpredictable in external validation cohorts, especially in young and elderly patients, and in high risk patients. NPI is an exception, which performed well in most independent populations. Therefore, models should be validated before being applied in another population.
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